Published Date : Dec 01, 2015
Earlier, in November 2015, the 26th USA-China Joint Commission on Commerce and Trade (JCCT) was held in Guangzhou, China where both the countries agreed to enhance their cooperation in drug supervision further. China and USA also planned to enhance their collaboration in the fields of food safety and actions against fake online sales of drugs. Other points of discussions at the trade were registration, approval, and clinical trials of medical devices and drugs. Cosmetics supervision for better health of the people was the other important factor that was discussed by China and USA.
Chinese Vice Premier Wang Yang, U.S. Trade Representative Michael Froman, and U.S. Secretary of Commerce Penny Pritzker were the members present at the conference. On behalf of the regulatory agency, the Vice Minister of China Food and Drug Administration (CFDA) Wu Zhen, attended the conference. Vice Minister Wu Zhen, at the conference, introduced the agreement that was reached by China and USA and emphasized that it is obligatory for the medical devices and drug agencies of China and USA to fight against sales of fake drugs and devices. Both, China and USA will continue to cooperate for fulfilling their aim.
The USA representatives, in the conference, announced that China has agreed to publish annual reports on medical devices and drugs evaluation. In 2014 and 2015, China had issued catalogues for clinical trial exemption for Class II and Class III medical devices. In 2016, it is expected that China will draft their second batch of catalogues for clinical trial exemption to expand the scope. The CFDA is planning to appoint dedicated people to take control of new innovative medical devices. The representatives would be responsible for taking care of the approval procedures and provide guidance upon request. China has agreed that a 30-day public comment period will be provided by the CFDA to implement the departmental rules.